IL2 and acute myeloid leukemia: Five out of 19 acute myeloid leukemia (AML) patients attained complete remission; however, high doses of interleukin-2 (IL-2) and high conditioning regimens triggered severe hematological as well as non-hematological toxicities in the patients [9].